CW Advisors LLC Has $5.30 Million Stock Position in Kenvue Inc. $KVUE

CW Advisors LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 77.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 252,980 shares of the company’s stock after purchasing an additional 110,040 shares during the quarter. CW Advisors LLC’s holdings in Kenvue were worth $5,295,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of KVUE. Trust Co. of Vermont lifted its position in shares of Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares during the last quarter. Truvestments Capital LLC acquired a new position in Kenvue during the first quarter worth about $37,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. First Pacific Financial acquired a new stake in shares of Kenvue in the 2nd quarter valued at approximately $54,000. Finally, Ransom Advisory Ltd bought a new stake in shares of Kenvue during the 1st quarter valued at approximately $56,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.4%

Shares of KVUE opened at $16.92 on Friday. The stock’s 50-day moving average price is $16.09 and its two-hundred day moving average price is $19.36. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a market capitalization of $32.42 billion, a PE ratio of 22.56 and a beta of 0.60. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the company earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s payout ratio is 110.67%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on KVUE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Redburn Partners set a $22.00 price target on Kenvue in a research note on Friday, September 26th. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Edward Jones cut Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Zacks Research raised Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.